Open AccessIntermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer
Author(s) -
Д. И. Юдин,
К. К. Лактионов,
D Marinov,
В. В. Бредер,
А. К. Аллахвердиев,
Т. Н. Борисова,
А. Х. Бекяшев,
К. П. Лактионов,
В. А. Алешин,
М. С. Ардзинба
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-19-122-125
Subject(s) - medicine , lung cancer , oncology , lung , metastasis , systemic therapy , overall survival , cancer , breast cancer
At the present time, a small group of patients with oligometastases (who have a solitary metastatic lesion in another organ along with the primary tumour of the lung) is differentiated among the patients with metastatic lung cancer. A total of 14 patients of the study citied in this article underwent a comprehensive treatment of oligometastatic non-small cell lung cancer (ONSCLC), which included systemic therapy and local influence on solitary metastasis. The median overall survival for this group was 20 months (16.0–32.6, CI 95%). The 1-year and 2-year overall survival rates accounted for 84.5 and 65.7%, respectively. The findings of the study demonstrate the possibilities of an aggressive approach to the treatment of patients with ONLDLC.